MRK: A second sotatercept market expansion prospect awaits in 1.5 million common heart failure patients who also suffer from pulmonary hypertension. While only preclinical animal model data suggest promising proof of concept, phase 2 placebo-controlled trial CADENCE-PH is due to readout by October 2024. Should this demonstrate a modest benefit, a successful phase 3 could generate multi billion additional revenue...
